Business -- mercurynews.com
Shares of Sunnyvale-based Pharmacyclics plunged more than 26 percent Monday - the fourth biggest drop in its history - after federal regulators refused to approve its drug Xcytrin to treat patients whose lung cancer has spread to their brain.